Michelle S. Bloom

Michelle S. Bloom

Auto-generated profile, based on publicly available information

Michelle S. Bloom

Natera, Inc., Austin, Texas

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2011 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
PSPeter Stirling
Peter Stirling
MBMichelle S. Bloom
Michelle S. Bloom
TSTejomayee Solanki-Patil
Tejomayee Solanki-Patil
SSStephanie Smith
Stephanie Smith
PSPayal Sipahimalani
Payal Sipahimalani
PHPhilip Hieter
Philip Hieter
Chromosome instability (CIN) is observed in most solid tumors and is linked to somatic mutations in genome integrity maintenance genes. The spectrum of mutations that cause CIN is only partly known and it is not possible to predict a priori all pathways whose disruption might lead to CIN. To address this issue, we generated a catalogue of CIN genes and pathways by screening ∼2,000 reduction-of-function alleles for 90% of essential genes in Saccharomyces cerevisiae. Integrating this with published CIN phenotypes for other yeast genes generated a systematic CIN gene dataset comprised of 692 genes. Enriched gene ontology terms defined cellular CIN pathways that, together with sequence orthologs, created a list of human CIN candidate genes, which we cross-referenced to published somatic mutation databases revealing hundreds of mutated CIN candidate genes. Characterization of some poorly characterized CIN genes revealed short telomeres in mutants of the ASTRA/TTT components TTI1 and ASA1. High-throughput phenotypic profiling links ASA1 to TTT (Tel2-Tti1-Tti2) complex function and to TORC1 signaling via Tor1p stability, consistent with the role of TTT in PI3-kinase related kinase biogenesis. The comprehensive CIN gene list presented here in principle comprises all conserved eukaryotic genome integrity pathways. Deriving human CIN candidate genes from the list allows direct cross-referencing with tumor mutational data and thus candidate mutations potentially driving CIN in tumors. Overall, the CIN gene spectrum reveals new chromosome biology and will help us to understand CIN phenotypes in human disease. Cancer results from mutations that alter the function of normal genes. The results of these mutations directly lead to the known properties of cancer cells, for example, over-proliferation or resistance to cellular death signals. An additional property of most tumors is chromosome instability (CIN)—the unequal distribution of DNA to the daughter cells following cell division. While CIN appears to be important for the formation of many tumors, the mutations that can lead to CIN are not well understood. Here we used a simple model cell, budding yeast, to systematically identify genes whose mutation can lead to CIN. Our data identify previously uncharacterized CIN genes that we show play a role in the stability of important cellular signaling proteins. Moreover, our results directly predict human CIN candidate genes, hundreds of which are mutated in tumors. Together our data create a resource for understanding new chromosome biology and the genetic basis of CIN in human cancers.

14 May 2019 in eLife
Verified
Journal Article
Open access
QWQian Wang
Qian Wang
CLChristin M Lepus
Christin M Lepus
HRHarini Raghu
Harini Raghu
LRLaurent L Reber
Laurent L Reber
MTMindy M Tsai
Mindy M Tsai
WRWilliam H Robinson
William H Robinson
Osteoarthritis is characterized by articular cartilage breakdown, and emerging evidence suggests that dysregulated innate immunity is likely involved. Here, we performed proteomic, transcriptomic, and electron microscopic analyses to demonstrate that mast cells are aberrantly activated in human and murine osteoarthritic joint tissues. Using genetic models of mast cell deficiency, we demonstrate that lack of mast cells attenuates osteoarthritis in mice. Using genetic and pharmacologic approaches, we show that the IgE/FcεRI/Syk signaling axis is critical for the development of osteoarthritis. We find that mast cell-derived tryptase induces inflammation, chondrocyte apoptosis, and cartilage breakdown. Our findings demonstrate a central role for IgE-dependent mast cell activation in the pathogenesis of osteoarthritis, suggesting that targeting mast cells could provide therapeutic benefit in human osteoarthritis.Editorial note: This article has been through an editorial process in which the authors decide how to respond to the issues raised during peer review. The Reviewing Editor's assessment is that all the issues have been addressed (see decision letter).

9 April 2019 in Nature Reviews Rheumatology
Verified
Journal Article
Closed access
PDF file
SRSamuel J. S. Rubin
Samuel J. S. Rubin
MBMichelle S. Bloom
Michelle S. Bloom
WRWilliam H. Robinson
William H. Robinson

5 October 2023 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
NDNeera K. Dahl
Neera K. Dahl
MBMichelle S. Bloom
Michelle S. Bloom
FCFouad T. Chebib
Fouad T. Chebib
DCDinah Clark
Dinah Clark
MWMaggie Westemeyer
Maggie Westemeyer
AGAli G. Gharavi
Ali G. Gharavi
Significance Statement: Accurate diagnosis of a patient's underlying cause of CKD can influence management and ultimately overall health. The single-arm, interventional, prospective Renasight Clinical Application, Review, and Evaluation study assessed the utility of genetic testing with a 385 gene kidney disease panel on the diagnosis and management of 1623 patients with CKD. Among 20.8% of patients who had positive genetic findings, half resulted in a new or reclassified diagnosis. In addition, a change in management because of genetic testing was reported for 90.7% of patients with positive findings, including treatment changes in 32.9%. These findings demonstrate that genetic testing has a significant effect on both CKD diagnosis and management. Background: Genetic testing in CKD has recently been shown to have diagnostic utility with many predicted implications for clinical management, but its effect on management has not been prospectively evaluated. Methods: Renasight Clinical Application, Review, and Evaluation RenaCARE (ClinicalTrials.gov NCT05846113) is a single-arm, interventional, prospective, multicenter study that evaluated the utility of genetic testing with a broad, 385 gene panel (the Renasight TM test) on the diagnosis and management of adult patients with CKD recruited from 31 US-based community and academic medical centers. Patient medical history and clinical CKD diagnosis were collected at enrollment. Physician responses to questionnaires regarding patient disease categorization and management were collected before genetic testing and 1 month after the return of test results. Changes in CKD diagnosis and management after genetic testing were assessed. Results: Of 1623 patients with CKD in 13 predefined clinical disease categories (ages, 18–96; median, 55 years), 20.8% ( n =338) had positive genetic findings spanning 54 genes. Positive genetic findings provided a new diagnosis or reclassified a prior diagnosis in 48.8% of those patients. Physicians reported that genetic results altered the management of 90.7% of patients with a positive genetic finding, including changes in treatment plan, which were reported in 32.9% of these patients. Conclusions: Genetic testing with a CKD-focused 385 gene panel substantially refined clinical diagnoses and had widespread implications for clinical management, including appropriate treatment strategies. These data support the utility of broader integration of panels of genetic tests into the clinical care paradigm for patients with CKD. Clinical Trial registry name and registration number: ClinicalTrials.gov, NCT05846113.

19 September 2019 in JCI Insight
Verified
Journal Article
Open access
PDF file
QWQian Wang
Qian Wang
KOKazuhiro Onuma
Kazuhiro Onuma
CLChanghao Liu
Changhao Liu
HWHeidi Wong
Heidi Wong
MBMichelle S. Bloom
Michelle S. Bloom
WRWilliam H. Robinson
William H. Robinson
Osteoarthritis (OA) is the leading cause of joint failure, yet the underlying mechanisms remain elusive, and no approved therapies that slow progression exist. Dysregulated integrin function was previously implicated in OA pathogenesis. However, the roles of integrin α V β 3 and the integrin-associated receptor CD47 in OA remain largely unknown. Here, transcriptomic and proteomic analyses of human and murine osteoarthritic tissues revealed dysregulated expression of α V β 3 , CD47, and their ligands. Using genetically deficient mice and pharmacologic inhibitors, we showed that α V β 3 , CD47, and the downstream signaling molecules Fyn and FAK are crucial to OA pathogenesis. MicroPET/CT imaging of a mouse model showed elevated ligand-binding capacities of integrin α V β 3 and CD47 in osteoarthritic joints. Further, our in vitro studies demonstrated that chondrocyte breakdown products, derived from articular cartilage of individuals with OA, induced α V β 3 /CD47-dependent expression of inflammatory and degradative mediators, and revealed the downstream signaling network. Our findings identify a central role for dysregulated α V β 3 and CD47 signaling in OA pathogenesis and suggest that activation of α V β 3 and CD47 signaling in many articular cell types contributes to inflammation and joint destruction in OA. Thus, the data presented here provide a rationale for targeting α V β 3 , CD47, and their signaling pathways as a disease-modifying therapy.

1 January 2015 in Molecular Biology of the Cell
Verified
Journal Article
Open access
PDF file
VGVincent Guacci
Vincent Guacci
JSJeremiah Stricklin
Jeremiah Stricklin
MBMichelle S. Bloom
Michelle S. Bloom
XGXuánzōng Guō
Xuánzōng Guō
MBMeghna Bhatter
Meghna Bhatter
DKDouglas Koshland
Douglas Koshland
Cohesin complex mediates cohesion between sister chromatids, which promotes high fidelity chromosome segregation. Eco1p acetylates the cohesin subunit Smc3p during S phase to establish cohesion. The current model posits that this Eco1p mediated acetylation promotes establishment by abrogating the ability of Wpl1p to destabilize cohesin binding to chromosomes. Here, we present data from budding yeast that is incompatible with this Wpl1p-centric model. Two independent in vivo assays show that a wpl1∆ fails to suppress cohesion defects of eco1∆ cells. Moreover, a wpl1∆ also fails to suppress cohesion defects engendered by blocking just the essential Eco1p acetylation sites on Smc3p (K112,K113). Thus, removing WPL1 inhibition is insufficient for generating cohesion without ECO1 activity. To elucidate how ECO1 promotes cohesion, we conducted a genetic screen and identified a cohesion activator mutation in the SMC3 head domain (D1189H). Smc3-D1189H partially restores cohesion in eco1∆ wpl1∆ or eco1 mutant cells but robustly restores cohesion in cells blocked for Smc3p K112 K113 acetylation. These data support two important conclusions. First, acetylation of K112 K113 region by Eco1p promotes cohesion establishment by altering Smc3p head function independent of its ability to antagonize Wpl1p. Second, Eco1p targets other than Smc3p K112 K113 are necessary for efficient establishment.